Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) Using International Council for Harmonisation (ICH) E2B(R3) Standards - 04/04/2023

Why It Matters

Standardizing electronic adverse‑event submissions improves data quality and accelerates safety signal detection, reducing compliance risk for pharmaceutical firms. The updated ICH E2B(R3) framework positions the U.S. market at the forefront of global pharmacovigilance interoperability.

Key Takeaways

• FDA hosted two 2023 meetings on ICH E2B(R3) FAERS upgrades.
• Focus on pre‑market and post‑market safety data submission standards.
• Materials, agendas, and slides are publicly available via Federal Register.
• Industry must adapt to new electronic ICSR requirements.
• Enhanced data standards aim to speed safety signal detection.

Pulse Analysis

The FDA’s Adverse Event Reporting System (FAERS) serves as the central repository for drug safety data in the United States. By aligning its electronic submission protocol with the International Council for Harmonisation’s E2B(R3) standard, the agency seeks to harmonize data formats across borders, facilitating faster aggregation and analysis of Individual Case Safety Reports (ICSRs). This shift reflects a broader industry trend toward real‑time pharmacovigilance, where digital interoperability reduces manual entry errors and shortens the time between adverse event detection and regulatory action.

During the April 4 and November 7, 2023 public meetings, FDA officials presented detailed technical specifications, including core data elements and business rules that will govern future submissions. The agenda materials and slide decks, now accessible via the Federal Register, outline the transition roadmap for both pre‑market and post‑market reporting streams under CDER and CBER. By documenting the evolution of the ICH E2B(R3) framework, the FDA provides pharmaceutical companies with a clear timeline to upgrade their internal reporting systems, ensuring that upcoming submissions meet the new electronic standards.

For drug manufacturers and biologics developers, the updated standards represent both a compliance imperative and an opportunity to enhance safety monitoring efficiency. Automated, standardized ICSR uploads enable more rapid signal detection, potentially shortening the interval between adverse event identification and corrective action. As global regulators converge on E2B(R3), firms that invest early in compatible infrastructure can expect smoother cross‑border submissions and reduced regulatory friction, ultimately supporting patient safety and market confidence.